无锡祥生医疗科技股份有限公司 2024 年度独立董事述职报告 本人宋安成作为无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公 司"）第三届董事会独立董事，根据《公司法》《证券法》《无锡祥生医疗科技股份 有限公司章程》《无锡祥生医疗科技股份有限公司独立董事工作制度》《无锡祥生 医疗科技股份有限公司独立董事专门会议工作制度》及有关法律、法规的规定, 忠 实履行职责，认真审议各项议案，积极出席相关会议，了解宏观经济形势和企业运 营状况，客观、独立、负责地参与公司决策，维护公司整体利益及全体股东特别是 中小股东的合法权益，自觉促进和维护董事会规范有效运作，为推动公司加快发展 建言献策。现将2024年度履职情况报告如下: 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 宋安成，男，1975年出生，中国国籍，无境外永久居留权，毕业于辽宁大学法 律专业，获硕士学位。2006年6月至2009年1月，就职于上海市建纬律师事务所任律 师；2009年1月至2010年10月，就职于上海恒隆律师事务所任合伙人；2010年10月至 2019年5月，就职于北京盈科（上海）律师事务所任高级合伙人；2019年5月至今 ...

4月24日祥生医疗发布2024年度分配预案，拟10派10元（含税），预计派现金额合计为1.12亿元。派现 额占净利润比例为79.62%，以该股2024年度成交均价计算，股息率为3.59%。这是公司上市以来，累计 第6次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派10元（含税） | 1.12 | 3.59 | | 2023.12.31 | 10派8元（含税） | 0.89 | 1.78 | | 2022.12.31 | 10派7元（含税） | 0.78 | 1.82 | | 2021.12.31 | 10转增4派5元（含税） | 0.40 | 1.03 | | 2020.12.31 | 10派8元（含税） | 0.64 | 1.14 | | 2019.12.31 | 10派10元（含税） | 0.80 | 2.08 | 证券时报·数据宝统计显示，公司今日公布了2024年报，共实现营业收入4.69亿元，同比下降3.13%，实 现净利润1.41亿元，同比下降4.0 ...

Financial Performance - Revenue for Q1 2025 was CNY 127.71 million, a decrease of 9.16% compared to CNY 140.60 million in the same period last year[4] - Net profit attributable to shareholders was CNY 41.61 million, down 8.62% from CNY 45.54 million year-on-year[4] - Basic and diluted earnings per share were both CNY 0.37, reflecting a decline of 9.76% from CNY 0.41 in the previous year[5] - Operating profit for Q1 2025 was ¥47.20 million, a decline of 9.3% compared to ¥52.41 million in Q1 2024[20] - Net profit for Q1 2025 was ¥41.61 million, down 8.5% from ¥45.54 million in Q1 2024[20] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 20.14% to CNY 21.04 million, compared to CNY 26.34 million in the same period last year[5] - Cash flow from operating activities for Q1 2025 was ¥21.04 million, down 20.3% from ¥26.34 million in Q1 2024[24] - Cash and cash equivalents at the end of Q1 2025 increased to ¥847.61 million from ¥239.77 million at the end of Q1 2024[25] - The company's cash and cash equivalents increased to RMB 1,016,854,712.62 from RMB 985,616,661.93, representing a rise of about 3.2%[15] Assets and Liabilities - Total assets increased by 1.56% to CNY 1,621.89 million from CNY 1,597.01 million at the end of the previous year[4] - The company's total liabilities decreased to RMB 159,670,323.30 from RMB 176,423,213.57, a decline of about 9.5%[17] - Total current liabilities decreased to RMB 149,367,227.11 from RMB 166,785,376.57, a reduction of approximately 10.5%[16] - The company's total equity increased to RMB 1,462,219,998.56 from RMB 1,420,586,554.05, reflecting a growth of about 2.8%[17] Research and Development - R&D expenses totaled CNY 17.46 million, representing 13.67% of revenue, a slight decrease from 13.74% in the previous year[5] - Research and development expenses for Q1 2025 were ¥17.46 million, a decrease of 11.2% from ¥19.66 million in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,509[10] - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 40.46% of the shares, totaling 45,360,000 shares[11] Other Financial Metrics - Financial expenses increased by 36.10%, primarily due to exchange rate fluctuations leading to increased foreign exchange losses[8] - The company reported non-recurring gains of CNY 2.74 million for the period[7] - The company reported a decrease in other comprehensive income, with a net loss of ¥518.53 thousand in Q1 2025 compared to a gain of ¥5.60 thousand in Q1 2024[20] - Accounts receivable rose to RMB 182,887,395.62, up from RMB 161,693,930.83, indicating an increase of approximately 13.1%[15] - Inventory decreased to RMB 107,496,307.15 from RMB 126,328,601.45, showing a decline of about 14.9%[15] - The non-current assets totaled RMB 195,821,486.94, slightly up from RMB 191,975,337.83, indicating a growth of approximately 2.0%[16] - The company's retained earnings increased to RMB 398,597,640.81 from RMB 356,983,110.49, representing a growth of approximately 11.6%[17] - The company experienced a net cash inflow from investment activities of ¥9.50 million in Q1 2025, slightly up from ¥9.44 million in Q1 2024[25]

Dividend Distribution - The company plans to distribute a cash dividend of 10 RMB per 10 shares, totaling approximately 111.87 million RMB, which represents 79.62% of the net profit attributable to shareholders for the year[5]. - The profit distribution plan has been approved by the board and will be submitted for shareholder approval at the 2024 annual general meeting[6]. - The total number of employees in the parent company and major subsidiaries is 537, with 186 in technical roles and 124 in sales[164]. - The cumulative cash dividend over the last three accounting years amounts to 279,861,731.30 RMB, with an average net profit of 130,942,887.15 RMB, resulting in a cash dividend ratio of 213.73%[178]. - The company has a cash dividend policy that prioritizes stable returns to shareholders while considering long-term growth and major investment plans[171]. Financial Performance - The company reported a revenue increase of 15% in 2024 compared to 2023, reaching a total of 500 million RMB[22]. - The company's operating revenue for 2024 was approximately ¥468.70 million, a decrease of 3.13% compared to ¥483.84 million in 2023[24]. - Net profit attributable to shareholders was approximately ¥140.51 million, down 4.08% from ¥146.48 million in the previous year[24]. - The net cash flow from operating activities increased significantly by 63.76% to approximately ¥140.68 million, compared to ¥85.91 million in 2023[24]. - The company's total assets reached approximately ¥1.60 billion, reflecting a growth of 4.89% from ¥1.52 billion at the end of 2023[24]. Research and Development - Research and development expenses increased by 10% in 2024, reflecting the company's commitment to innovation and new technology[22]. - The R&D investment as a percentage of operating revenue increased to 16.99%, up from 15.93% in the previous year[25]. - The company invested CNY 79.63 million in R&D, accounting for 16.99% of its revenue, and received 48 new patent authorizations, including 30 invention patents[34]. - The company has accumulated a total of 61 core technologies, focusing on continuous R&D investment to drive innovation in ultrasound medical imaging equipment[76]. - The company has introduced 10 new core technologies during the reporting period, enhancing portable ultrasound and AI ultrasound capabilities[75]. Market Position and Strategy - The company achieved a market share of 15% in the domestic ultrasound device market, positioning itself as a key player[22]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the medical imaging sector[22]. - The company aims to become a global leader in specialized ultrasound by focusing on high-end color ultrasound, portable devices, and AI integration[133]. - The company has established a nationwide sales network covering over 30 provinces and regions in China, with significant growth potential in the domestic market due to its differentiated technology and international quality standards[63]. - The company is actively involved in the development of AI-assisted diagnostic technologies, enhancing the capabilities of its medical imaging devices[65]. Corporate Governance - The company has established a governance structure that ensures independence and coordination among the shareholders' meeting, board of directors, and management[141]. - The company has not reported any issues regarding independence or operational capability concerning its controlling shareholders[141]. - The board of directors includes members with extensive experience, such as the chairman and general manager, who has held the position since August 2023[145]. - The company has maintained a stable shareholding structure, with no changes in the number of shares held by directors during the reporting period[145]. - The company has established a remuneration and assessment committee to draft remuneration proposals for senior management[153]. Risk Management - The company has provided a detailed risk analysis regarding potential operational risks in the report[3]. - The company is facing risks related to product development failures due to the complexity of ultrasound technology[89]. - There is a risk of technology leakage that could negatively impact the company's competitive advantage[91]. - The company has not reported any significant risk issues reported by the supervisory board during the reporting period[163]. - The company has established a unified management process for subsidiaries to enhance operational efficiency and risk management[190]. Social Responsibility and ESG - The company emphasizes the importance of ESG practices, integrating sustainable development into daily operations and strategic decisions[193]. - The company actively participates in social responsibility initiatives, including medical assistance programs[192]. - The company has received ESG ratings of BB from Wind and Huazheng, and BBB from Zhidin[198]. - The company integrates green energy-saving design concepts into its product development, aiming to reduce energy costs and carbon emissions[197]. - The company has implemented strict waste classification, storage, and processing procedures to enhance recycling rates and reduce secondary pollution[197].

无锡祥生医疗科技股份有限公司 董事会审计委员会 对 2024 年会计师事务所履行监督职责情况报告 无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公司"）聘请容诚 会计师事务所（特殊普通合伙）（以下简称"容诚"）作为公司 2024 年度境内财务 报告审计机构和内部控制审计机构。 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通 合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证 券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26，首席合伙人刘维。 截至 2024 年 12 月 31 日，容诚会计师事务所共有合伙人 212 人，共有注册 会计师 1552 人，其中 781 人签署过证券服务业务审计报告。 （二）聘任会计师事务所履行的程序 公司于 2024 年 4 月 18 日召开的第三届董事会独立董事专门会议第一次会议、 第三届董事会审计委员会第三次会议、第三届董事会第五次会议、第三届监事会 第五次会议审议通过了《 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-009 无锡祥生医疗科技股份有限公司 关于开展外汇套期保值业务的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司拟开展的外汇套期保值业务资金额度折合不超过8000万美元（含本 数）或其他等值外币（额度范围内资金可滚动使用），资金来源为自有资金。额 度有效期为自公司2024年年度股东大会审议通过之日起12个月。 公司的外汇套期保值业务以正常生产经营为基础，以规避和防范汇率风 险为目的，不进行单纯以盈利为目的的投机和套利交易。 本事项尚需提交公司2024年年度股东大会审议。 无锡祥生医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第三届董事会第十二次会议和第三届监事会第十一次会议，审议通过了 《关于开展外汇套期保值业务的议案》，同意公司为规避外汇市场风险，使用自 有资金与银行开展外汇套期保值业务。该议案尚需提交公司 2024 年年度股东大 会审议。现将具体情况公告如下： 一、开展外汇套期保值业务的必要性 公司出 ...

报告期内，公司董事会审计委员会共召开会议 3 次，全体委员均亲自出席，具 体情况如下： 无锡祥生医疗科技股份有限公司 2024 年度董事会审计委员会工作报告 根据中国证监会《上市公司治理准则》《上海证券交易所科创板股票上市规则》 和《无锡祥生医疗科技股份有限公司章程》《无锡祥生医疗科技股份有限公司董事会 审计委员会工作细则》等有关规定，无锡祥生医疗科技股份有限公司（以下简称"祥 生医疗"或"公司"）董事会审计委员会本着勤勉尽责的原则，认真履行了审计监督 职责。现将公司审计委员会 2024 年度工作情况报告如下： 一、审计委员会基本情况 第三届董事会审计委员会共有 3 名委员：李寿喜先生（主任委员）、宋安成先生、 莫善珏先生。其中主任委员具有专业财会知识。 二、审计委员会召开会议情况 | 时间 | | 届次 1. | 审议事项 《关于 2023 年年度报告正文及其摘要中财务数 | | --- | --- | --- | --- | | | | 2. | 据的议案》 《关于聘请 2024 年度审计机构的议案》 | | | | 3. | 《关于 2023 年度利润分配方案的议案》 | | | | 第三届董事会 4. ...

无锡祥生医疗科技股份有限公司 会计师事务所履职情况评估报告 容诚会计师事务所共承担 394 家上市公司 2023 年年报审计业务，审计收费 总额 48,840.19 万元，客户主要集中在制造业（包括但不限于计算机、通信和其 他电子设备制造业、专用设备制造业、电气机械和器材制造业、化学原料和化学 制品制造业、汽车制造业、医药制造业、橡胶和塑料制品业、有色金属冶炼和压 延加工业、建筑装饰和其他建筑业）及信息传输、软件和信息技术服务业，水利、 环境和公共设施管理业，科学研究和技术服务业，批发和零售业等多个行业。容 诚会计师事务所对无锡祥生医疗科技股份有限公司所在的相同行业上市公司审 计客户家数为 282 家。 二、执业记录 无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公司"）聘请容诚 会计师事务所（特殊普通合伙）（以下简称"容诚"）作为公司 2024 年度境内财务 报告审计机构和内部控制审计机构。 根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员会颁 布的《国有企业、上市公司选聘会计师事务所管理办法》，公司对容诚 2024 年度 审计过程中的履职情况进行评估。经评估，公司认为容诚在资质等方面 ...

根据公司发展计划，为满足公司日常经营资金需要，2025 年度公司拟向银 行申请不超过人民币 4 亿元（含本数）的综合授信额度（最终以各家银行实际审 批的授信额度为准），综合授信品种包括但不限于短期流动资金贷款、贸易融资 等。 以上授信额度不等于公司的实际融资金额，具体融资金额及品种将视公司业 务发展的实际需求合理确定。本次申请综合授信额度事项有效期为自公司 2024 年年度股东大会审议通过后至 2025 年年度股东大会召开之日止。 证券代码：688358 证券简称：祥生医疗 公告编号：2025-008 无锡祥生医疗科技股份有限公司 关于公司向银行申请综合授信额度的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 4 月 24 日召开第三届董事会第十二次会议和第三届监事会第 十一次会议，审议通过了《关于公司向银行申请综合授信额度的的议案》。现将 具体情况公告如下： 2025 年 4 月 25 日 为提高工作效率，公司董事会提请股东大会授权公司经营管理层根据公司实 际经营情况的需要，在上 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-005 无锡祥生医疗科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙）。 一、拟聘任会计师事务所的基本情况 (一) 机构信息 1、基本信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通 合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证 券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26，首席合伙人刘维。 2、人员信息 截至 2024 年 12 月 31 日，容诚会计师事务所共有合伙人 212 人，共有注册 会计师 1552 人，其中 781 人签署过证券服务业务审计报告。 3、业务规模 容诚会计师事务所经审计的 2023 年度收入总额为 287,22 ...